Optimal Therapies for Relapsed/Refractory Multiple Myeloma
Nina Shah, MD, details the process to choose optimal therapeutic options for patients with relapsed/refractory multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: For patients with relapsed or refractory myeloma, choosing the most optimal therapy depends on what they had before and what they tolerated. In the earlier lines, the go-to therapy has been a CD38 monoclonal antibody in combination with something. We cannot ignore the very impressive data that has been shown by CD38 monoclonal antibody therapy in combination with carfilzomib [Kyprolis], both from the CANDOR study [NCT03158688] and IKEMA study [NCT03275285]. [We saw] impressive progression-free survival data there. That’s starting to take hold a lot more, especially for patients with aggressive early relapses.
In the later relapses, I’m very impressed with the BCMA [B-cell maturation antigen] CAR T-cell therapy and the BCMA bispecific T-cell engager data. There’s also a potential role for the novel CELMoDs [cereblon E3 ligase modulators] if you incorporate them in combination. Then finally, there are drugs like selinexor [Xpovio] that can be used particularly in combination with other drugs that a patient may have seen long time ago but is ready to be exposed to [again].
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
